Pfizer completes community vaccine trials for Prevenar

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE +0.8%) says it's completed pneumonia case accrual data in a trial of patients over 65 to evaluate whether Prevenar 13 is effective in preventing community-acquired pneumonia cause by 12 pneumococcal strains included in the vaccine.

The trial, which involves about 85,000 people, was needed to fulfil regulatory commitments under the FDA's accelerated approval program.